Compare Stocks: PMN, INDP, SRZN, and OCGN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INDP Indaptus Therapeutics	$2.38 +12.3%	$1.94	$0.92 ▼ $5.96	$317.12M	0.97	1.59 million shs	567,914 shs
OCGN Ocugen	$1.02 +2.0%	$1.22	$0.97 ▼ $2.73	$345.89M	2.27	9.13 million shs	3.29 million shs
PMN Promis Neurosciences	$9.40 +0.2%	$13.42	$6.27 ▼ $27.40	$84.30M	-0.26	40,403 shs	27,303 shs
SRZN Surrozen	$29.32 -2.3%	$22.80	$11.39 ▼ $37.83	$340.41M	0.47	938,108 shs	645,978 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INDP Indaptus Therapeutics	0.00%	-38.18%	+105.17%	-21.45%	-32.00%
OCGN Ocugen	0.00%	0.00%	-24.44%	-32.45%	-39.29%
PMN Promis Neurosciences	0.00%	-16.59%	-27.13%	-29.59%	-17.54%
SRZN Surrozen	0.00%	-0.74%	+30.08%	+17.66%	+114.64%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INDP Indaptus Therapeutics	$2.38 +12.3%	$1.94	$0.92 ▼ $5.96	$317.12M	0.97	1.59 million shs	567,914 shs
OCGN Ocugen	$1.02 +2.0%	$1.22	$0.97 ▼ $2.73	$345.89M	2.27	9.13 million shs	3.29 million shs
PMN Promis Neurosciences	$9.40 +0.2%	$13.42	$6.27 ▼ $27.40	$84.30M	-0.26	40,403 shs	27,303 shs
SRZN Surrozen	$29.32 -2.3%	$22.80	$11.39 ▼ $37.83	$340.41M	0.47	938,108 shs	645,978 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INDP Indaptus Therapeutics	0.00%	-38.18%	+105.17%	-21.45%	-32.00%
OCGN Ocugen	0.00%	0.00%	-24.44%	-32.45%	-39.29%
PMN Promis Neurosciences	0.00%	-16.59%	-27.13%	-29.59%	-17.54%
SRZN Surrozen	0.00%	-0.74%	+30.08%	+17.66%	+114.64%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
INDP Indaptus Therapeutics	1.00	Sell	N/A	N/A
OCGN Ocugen	2.60	Moderate Buy	$9.50	831.37% Upside
PMN Promis Neurosciences	2.88	Moderate Buy	$34.00	261.70% Upside
SRZN Surrozen	2.71	Moderate Buy	$48.33	64.85% Upside

Current Analyst Ratings Breakdown

Latest PMN, INDP, SRZN, and OCGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/25/2026	SRZN Surrozen	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$44.00 ➝ $54.00
9/8/2026	PMN Promis Neurosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/21/2026	PMN Promis Neurosciences	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$29.00
8/20/2026	SRZN Surrozen	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$51.00
8/20/2026	SRZN Surrozen	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$51.00
8/11/2026	OCGN Ocugen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/10/2026	SRZN Surrozen	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$44.00
7/28/2026	PMN Promis Neurosciences	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$35.00 ➝ $69.00
7/28/2026	SRZN Surrozen	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/27/2026	PMN Promis Neurosciences	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$20.00
7/27/2026	PMN Promis Neurosciences	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$20.00

(Data available from 10/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
INDP Indaptus Therapeutics	N/A	N/A	N/A	N/A	$1.40 per share	N/A
OCGN Ocugen	$4.41M	78.43	N/A	N/A	($0.04) per share	-25.50
PMN Promis Neurosciences	N/A	N/A	N/A	N/A	($0.58) per share	N/A
SRZN Surrozen	$3.48M	97.82	N/A	N/A	($19.21) per share	-1.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
INDP Indaptus Therapeutics	-$20.85M	-$6.33	N/A	N/A	N/A	N/A	-302.89%	-203.49%	11/17/2026 (Estimated)
OCGN Ocugen	-$67.85M	-$0.26	N/A	N/A	N/A	N/A	-127,987.80%	-115.95%	11/4/2026 (Estimated)
PMN Promis Neurosciences	-$39.72M	-$8.54	N/A	N/A	N/A	N/A	-143.09%	-109.15%	11/11/2026 (Estimated)
SRZN Surrozen	-$242.03M	-$40.55	N/A	N/A	N/A	-2,885.33%	N/A	-93.62%	11/6/2026 (Estimated)

Latest PMN, INDP, SRZN, and OCGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	INDP Indaptus Therapeutics	-$1.57	-$0.02	+$1.55	-$0.02	N/A	N/A
8/13/2026	Q2 2026	PMN Promis Neurosciences	-$1.38	-$1.28	+$0.10	-$1.28	N/A	N/A
8/6/2026	Q2 2026	OCGN Ocugen	-$0.0533	-$0.07	-$0.0167	-$0.07	$0.89 million	$1.49 million
8/6/2026	Q2 2026	SRZN Surrozen	-$1.29	-$0.41	+$0.88	-$0.41	$0.47 million	$5.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
INDP Indaptus Therapeutics	N/A	N/A	N/A	N/A	N/A
OCGN Ocugen	N/A	N/A	N/A	N/A	N/A
PMN Promis Neurosciences	N/A	N/A	N/A	N/A	N/A
SRZN Surrozen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
INDP Indaptus Therapeutics	N/A	19.49	19.49
OCGN Ocugen	4.17	0.80	0.80
PMN Promis Neurosciences	N/A	7.85	7.85
SRZN Surrozen	N/A	12.14	12.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
INDP Indaptus Therapeutics	7.06%
OCGN Ocugen	10.27%
PMN Promis Neurosciences	50.13%
SRZN Surrozen	66.57%

Insider Ownership

Company	Insider Ownership
INDP Indaptus Therapeutics	9.94%
OCGN Ocugen	3.95%
PMN Promis Neurosciences	1.50%
SRZN Surrozen	31.74%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
INDP Indaptus Therapeutics	5	133.24 million	120.00 million	Not Optionable
OCGN Ocugen	116	339.11 million	325.72 million	Optionable
PMN Promis Neurosciences	11	8.97 million	8.83 million	Not Optionable
SRZN Surrozen	44	11.61 million	7.93 million	Not Optionable

PMN, INDP, SRZN, and OCGN Headlines

Recent News About These Companies

Financial Contrast: Surrozen (NASDAQ:SRZN) vs. Halozyme Therapeutics (NASDAQ:HALO)

October 3 at 5:28 AM | americanbankingnews.com

Surrozen to Advance Potential Eye Drug into Clinical Development Following FDA Clearance

October 3 at 3:07 AM | finance.yahoo.com

Surrozen's SZN-8141 IND Cleared By FDA For Diabetic Macular Edema

October 2 at 12:04 PM | rttnews.com

Surrozen secures FDA clearance for SZN-8141 and $95.1 million financing

October 2 at 12:04 PM | grafa.comG

Surrozen advances diabetic macular edema candidate into clinic after IND clearance

October 2 at 12:04 PM | msn.com

Surrozen Wins FDA IND Clearance for SZN-8141 Program

October 2 at 8:31 AM | tipranks.com

Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema

October 2 at 8:00 AM | globenewswire.com

Surrozen, Inc. (SRZN) Latest Stock News & Headlines - Yahoo Finance

October 1 at 11:09 PM | finance.yahoo.com

Surrozen, Inc. (NASDAQ:SRZN) Shares Shorted: Short Interest Up 51.9% in September

October 1 at 8:59 AM | marketbeat.com

Surrozen, Inc. (SRZN) Stock Price, News, Quote & History - Yahoo Finance

September 30, 2026 | finance.yahoo.com

FY2030 EPS Estimates for Surrozen Boosted by HC Wainwright

September 29, 2026 | americanbankingnews.com

HC Wainwright Has Positive View of Surrozen FY2030 Earnings

September 29, 2026 | marketbeat.com

Surrozen, Inc. (NASDAQ:SRZN) Receives Average Rating of "Moderate Buy" from Analysts

September 23, 2026 | americanbankingnews.com

Surrozen, Inc. (NASDAQ:SRZN) Given Average Recommendation of "Moderate Buy" by Brokerages

September 18, 2026 | marketbeat.com

Surrozen, Inc. (SRZN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 16, 2026 | seekingalpha.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Surrozen (SRZN), Liquidia Technologies (LQDA) and Universal Health (UHS)

September 11, 2026 | theglobeandmail.com

Surrozen Submits IND Application For SZN-8141 In Diabetic Macular Edema

September 8, 2026 | rttnews.com

Surrozen Announces Submission of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema

September 8, 2026 | globenewswire.com

Surrozen to Present at Upcoming Healthcare Investor Conferences

September 2, 2026 | globenewswire.com

Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update

August 6, 2026 | globenewswire.com

Surrozen (NASDAQ:SRZN) Major Shareholder Sells $6,906,250.00 in Stock

July 29, 2026 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMN, INDP, SRZN, and OCGN Company Descriptions

Indaptus Therapeutics NASDAQ:INDP

$2.38 +0.26 (+12.26%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$2.36 -0.02 (-0.92%)

As of 10/2/2026 07:30 PM Eastern

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Ocugen NASDAQ:OCGN

$1.02 +0.02 (+2.00%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$1.01 -0.01 (-0.49%)

As of 10/2/2026 07:58 PM Eastern

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Promis Neurosciences NASDAQ:PMN

$9.40 +0.02 (+0.21%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$9.43 +0.03 (+0.27%)

As of 10/2/2026 07:30 PM Eastern

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

Surrozen NASDAQ:SRZN

$29.32 -0.68 (-2.27%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$29.54 +0.22 (+0.73%)

As of 10/2/2026 07:48 PM Eastern

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PMN, INDP, SRZN, and OCGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PMN, INDP, SRZN, and OCGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PMN, INDP, SRZN, and OCGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMN, INDP, SRZN, and OCGN Company Descriptions

Indaptus Therapeutics NASDAQ:INDP

Ocugen NASDAQ:OCGN

Promis Neurosciences NASDAQ:PMN

Surrozen NASDAQ:SRZN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PMN, INDP, SRZN, and OCGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PMN, INDP, SRZN, and OCGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PMN, INDP, SRZN, and OCGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMN, INDP, SRZN, and OCGN Company Descriptions

Indaptus Therapeutics NASDAQ:INDP

Ocugen NASDAQ:OCGN

Promis Neurosciences NASDAQ:PMN

Surrozen NASDAQ:SRZN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools